More importantly, we screened out a small molecule HIF-2α inhibitor that synergizes with PTX for inhibition of tumor growth in vitro and in vivo, and represents a promising candidate for targeted therapy of breast cancer. This evidence concerns the gene EPAS1 and breast carcinoma.